BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
See today's BioWorld
Home
» Stay 'tuned': Lyric series A $20M, but company mum about details of GI effort
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Stay 'tuned': Lyric series A $20M, but company mum about details of GI effort
Feb. 27, 2015
By
Randy Osborne
No Comments
Only willing to sing half the song at the moment, Lyric Pharmaceuticals Inc. drew $20.4 million in a series A round that will pay for two studies with a compound targeting a gastrointestinal (GI) condition, including a proof-of-concept experiment.
BioWorld